Top Page
Shandong Xinhua Pharmaceutical Company Limited Class H
(0719)
Shandong Xinhua Pharmaceutical Company Limited Class H (0719) vs. iShares MSCI Hong Kong ETF (EWH)
Shandong Xinhua Pharmaceutical Company Limited Class H Business Overview & Revenue Model
Shandong Xinhua Pharmaceutical Company Limited Class H Financial Statement Overview
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 8.42B | 8.47B | 8.10B | 7.50B | 6.56B | 6.01B | Gross Profit |
| 1.82B | 2.04B | 2.32B | 2.04B | 1.77B | 1.81B | EBIT |
| 506.98M | 534.37M | 534.58M | 476.71M | 425.59M | 422.49M | EBITDA |
| 605.22M | 1.11B | 1.09B | 1.01B | 840.20M | 856.79M | Net Income Common Stockholders |
| 440.24M | 470.02M | 496.51M | 411.06M | 348.55M | 324.86M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 1.34B | 1.25B | 918.33M | 1.16B | 744.66M | 855.77M | Total Assets |
| 7.04B | 9.02B | 8.29B | 8.27B | 7.33B | 7.09B | Total Debt |
| 1.50B | 1.35B | 1.08B | 1.38B | 1.04B | 1.09B | Net Debt |
| 163.66M | 107.78M | 166.60M | 225.11M | 299.09M | 231.77M | Total Liabilities |
| 3.88B | 3.80B | 3.51B | 3.92B | 3.68B | 3.70B | Stockholders Equity |
| 3.02B | 4.99B | 4.55B | 4.13B | 3.47B | 3.22B |
| Cash Flow | Free Cash Flow | ||||
| 50.64M | 155.19M | ― | 513.48M | 9.89M | 140.00M | Operating Cash Flow |
| 39.34M | 367.61M | 265.28M | 758.24M | 259.12M | 420.19M | Investing Cash Flow |
| -50.54M | ― | ― | ― | ― | ― | Financing Cash Flow |
| 251.79M | 184.78M | -196.11M | ― | ― | 35.04M |
Shandong Xinhua Pharmaceutical Company Limited Class H Technical Analysis
Shandong Xinhua Pharmaceutical Company Limited Class H Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $101.88B | 22.16 | 13.20% | 4.42% | -9.60% | -27.18% | |
76 Outperform | $26.05B | 14.76 | 10.17% | 3.99% | -8.91% | -34.40% | |
72 Outperform | $964.10B | 6.55 | 6.13% | 11.71% | 37.04% | ||
70 Outperform | HK$9.37B | 8.80 | 8.89% | 4.93% | 4.91% | -11.80% | |
66 Neutral | $81.38B | 42.88 | 6.14% | 1.32% | 7.63% | -24.23% | |
65 Neutral | $67.02B | 14.71 | 6.22% | 1.96% | -2.82% | 11.93% | |
54 Neutral | $5.31B | 3.26 | -45.10% | 2.79% | 16.76% | 0.02% |
Shandong Xinhua Pharmaceutical Company Limited Class H Corporate Events
Shandong Xinhua Pharmaceutical Company Limited has released its unaudited financial results for the first quarter of 2025, showing a slight decrease in operating income by 1.81% compared to the same period last year. The company reported a significant decline in net profit attributable to shareholders, down by 20.99%, and a substantial drop in net cash flow from operating activities by 77.87%. Despite these challenges, the company’s total assets increased by 2.77%, and net assets attributable to shareholders rose by 3.28%, indicating a stable asset base.
Shandong Xinhua Pharmaceutical Company Limited announced that its Aspirin Enteric-coated Tablets have passed the Generics Drugs Consistency Evaluation, receiving approval from the National Medical Products Administration. This approval signifies a positive step for the company, enhancing its product offerings and potentially strengthening its position in the pharmaceutical market.
Shandong Xinhua Pharmaceutical Company Limited has received approval from the National Medical Products Administration for a change in the marketing license holder of its Epalrestat tablets. This approval is part of a broader agreement with Beijing Minkang Baicao Pharmaceutical Technology Company Limited, which involves the transfer of production technology and marketing authorization holder status for Mecobalamin tablets to Xinhua Pharmaceutical. This strategic move is expected to enhance Xinhua Pharmaceutical’s market position and operational capabilities in the pharmaceutical industry.
Shandong Xinhua Pharmaceutical Company Limited has announced that it has received a Drug Registration Certificate for its Pregabalin oral solution from the National Medical Products Administration. This approval marks a significant step for the company, allowing it to produce and market the drug, which is used in the treatment of postherpetic neuralgia, fibromyalgia, and partial seizures, thereby potentially enhancing its market position and expanding its product offerings.
Shandong Xinhua Pharmaceutical Company Limited has announced the receipt of the Drug Registration Certificate for its Memantine hydrochloride oral solution from the National Medical Products Administration. This approval marks a significant milestone for the company, enabling it to proceed with the production and sale of the drug, potentially enhancing its market position in the pharmaceutical industry.
Shandong Xinhua Pharmaceutical Company Limited has announced a board meeting scheduled for April 28, 2025, to consider and approve the unaudited results for the first quarter of 2025. This meeting is significant as it will provide insights into the company’s financial performance and could impact its market positioning and stakeholder confidence.
Shandong Xinhua Pharmaceutical Company Limited announced that its Aminophylline Tablets have passed the Consistency of Quality and Efficacy Evaluation for Generic Drugs, as approved by the National Medical Products Administration. This approval is a significant milestone for the company, potentially enhancing its market position by ensuring the quality and efficacy of its generic drugs, which could lead to increased trust and demand from healthcare providers and patients.
Shandong Xinhua Pharmaceutical Company Limited has received approval from the National Medical Products Administration for the change of marketing license holder for its Eszolam tablets. This approval follows a contract signed with Guangxi Dahai Sunshine Pharmaceutical Company Limited for the transfer of the Marketing Authorization Holder status and related technical ownership rights, marking a significant step in the company’s strategic operations.
Shandong Xinhua Pharmaceutical Company Limited has announced its audited consolidated financial results for the year ending December 31, 2024. The results, prepared in accordance with China Accounting Standards for Business Enterprises, reflect the company’s ongoing commitment to transparency and adherence to regulatory standards, potentially impacting its market positioning and stakeholder confidence.
Shandong Xinhua Pharmaceutical Company Limited has announced proposed amendments to its Articles of Association following an increase in its issued share capital due to the exercise of options under its Share Option Scheme. Additionally, the company has absorbed Ronghua (Zibo) Property Services Co., Ltd., expanding its business scope to include property management and real estate rental services. These changes necessitate revisions to the company’s Articles of Association, which will be subject to shareholder approval at a general meeting.
Shandong Xinhua Pharmaceutical Company Limited has announced a final cash dividend of RMB 0.25 per share for the financial year ending December 31, 2024. The announcement reflects the company’s financial performance and commitment to returning value to shareholders, although specific details regarding the payment date and withholding tax are yet to be disclosed.
Shandong Xinhua Pharmaceutical Company Limited has announced that its board of directors will hold a meeting on March 28, 2025, to consider and approve the audited annual results for the year ending December 31, 2024. The meeting will also discuss the recommendation of a final dividend and address any other business matters. This announcement indicates the company’s ongoing commitment to transparency and shareholder engagement, potentially impacting its market positioning and stakeholder relations.
Shandong Xinhua Pharmaceutical Company Limited has announced that it has received the Drug Registration Certificate for its Pentazocine injection from the National Medical Products Administration. This approval marks a significant step for the company, allowing it to proceed with the production and sale of the drug, thereby potentially enhancing its market position in the pharmaceutical industry.
Shandong Xinhua Pharmaceutical Company Limited has received approval from the National Medical Products Administration for the supplementary application concerning the transfer of marketing authorization holder of Clopidogrel Hydrogen Sulfate Tablets. This approval follows a technology transfer agreement with Beijing Sihuan Pharmaceutical Company Limited, allowing Xinhua Pharmaceutical to acquire the marketing and sales license, along with related rights and interests, for the product. This strategic move is expected to enhance Xinhua Pharmaceutical’s market position and expand its product offerings in the pharmaceutical sector.